Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *

@article{Gram1995MoclobemideAS,
  title={Moclobemide, a substrate of CYP2C19 and an inhibitor of CYP2C19, CYP2D6, and CYP1A2: A panel study *},
  author={Lennart Gram and Theodor W. Guentert and Susan Grange and Kirsten Kjeldgaard Vistisen and Kim Br{\o}sen},
  journal={Clinical Pharmacology \& Therapeutics},
  year={1995},
  volume={57}
}
The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S‐mephenytoin (n = 7) or extensive metabolizers of S‐mephenytoin (n = 8). All were extensive metabolizers of sparteine. Poor metabolizers of S‐mephenytoin had lower moclobemide clearance values (median, single dose: 16.1 versus 43.2 L · hr−1; steady state: 13.4 versus 22.1 L… Expand
Omeprazole hydroxylation is inhibited by a single dose of moclobemide in homozygotic EM genotype for CYP2C19.
TLDR
It is concluded that physicians prescribing moclobemide should pay attention to its pharmacokinetic interactions even on the first day of coadministration with CYP2C19 substrates. Expand
The role of cytochrome P450 2D6 in the metabolism of moclobemide
TLDR
Results indicate that the cytochromal isoenzyme CYP2D6 does not play a major role in the metabolic degradation of moclobemide, and limited CYP 2D6 activities because of a genetic defect or co-medications with CYP1D6 substrates should therefore not give rise to elevated moclOBemide blood levels. Expand
Inhibition of dextromethorphan metabolism by moclobemide
TLDR
It is indicated that moclobemide can affect the pharmacokinetics of drugs that are mainly metabolized by CYP2D6, whereas the N-demethylation of dextrorphan to hydroxymorphinan was not affected. Expand
Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19- and CYP3A4/5-phenotyped patients.
TLDR
A stereoselectivity in the metabolism of TRI has been found, with a preferential N-demethylation of (D)-TRI and a preferential hydroxylation of L-TRI, and CYP2D6 appears to be involved in the demethylation pathway. Expand
Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine
TLDR
This investigation confirms that paroxetine and fluxetine are potent inhibitors of CYP2D6, that fluvoxamine and fluoxettine are moderate inhibitors of CyP2C19 and that fluVoxamine is a potent inhibitor of CYp1A2 in humans in vivo. Expand
Tolterodine does not affect the human in vivo metabolism of the probe drugs caffeine, debrisoquine and omeprazole.
TLDR
Tolterodine, administered at twice the expected therapeutic dosage, did not change the disposition of the probe drugs debrisoquine, omeprazole and caffeine and thus had no detectable effect on the activities of CYPs 2D6, 2C19, 3A4 and 1A2. Expand
Clinical Significance of the Cytochrome P450 2C19 Genetic Polymorphism
TLDR
Genotyping for the common alleles of CYP2C19 before initiating PPIs for the treatment of reflux disease and H. pylori infection is a cost effective tool to determine appropriate duration of treatment and dosage regimens and, because of its narrow therapeutic range, genotyping of CYPs in addition to CYP1C9 may be needed to optimise the dosage of phenytoin. Expand
Cytochrome P450 enzymes contributing to demethylation of maprotiline in man.
TLDR
It appears that CYP2D6 and CYPIA2 contribute to maprotiline demethylation, and for plasma concentrations of 1 microM 83% (mean) of desmethylmap Rotiline formation in vivo is expected to be mediated by CYP 2D6 while 17% only may be attributed to CYPia2 activity. Expand
Polymorphism of Human Cytochrome P450 2D6 and Its Clinical Significance
TLDR
There is a considerable variability in the CYP2D6 allele distribution among different ethnic groups, resulting in variable percentages of PMs, IMs, EMs and UMs in a given population and the number of alleles is still growing. Expand
Clinical implications of CYP2C19 polymorphism for tailor-made pharmacotherapy
TLDR
A pronounced interracial difference in the pharmacokinetics of several drugs has been observed between PM and EM subjects, and variability may account for the interracial differences in drug responsiveness to drugs whose metabolism is regulated by the same genetic factor. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 38 REFERENCES
Single‐dose kinetics of clomipramine: Relationship to the sparteine and S‐mephenytoin oxidation polymorphisms
TLDR
Evidence is provided that the 2‐ and 8‐hydroxylation of clomipramine are catalyzed by CYP2D6 and that the N‐demethylation is catalyzed in part by CYp2C. Expand
The mephenytoin oxidation polymorphism is partially responsible for the N‐demethylation of imipramine
TLDR
In conclusion, this and an earlier study show that the oxidation of imipramine is mediated by means of two different polymorphic P450 isozymes, 2‐hydroxylation by way of the sparteine oxygenase (P450IID6) and demethylation by Way of the mephenytoin oxygen enzyme (P 450IIC8). Expand
Pharmacokinetics of Citalopram in Relation to the Sparteine and the Mephenytoin Oxidation Polymorphisms
TLDR
It was shown that the citalopram elimination partially depends on the mephenytoin oxygenase, since steady-state serum concentration, half-life, and area under the serum concentration/time curve for cITALopram were significantly higher in poor metabolizers of mephenYtoin than in extensive metabolizer of me Pheny toin. Expand
Imipramine metabolism in relation to the sparteine and mephenytoin oxidation polymorphisms--a population study.
TLDR
The demethylation ratios were higher in 80 smokers than in 245 non-smokers, which indicates that CYP1A2, which is induced by cigarette smoking, also catalyzes the N-demethylation of imipramine. Expand
S‐mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin
TLDR
Coadministration of debrisoquin and mephenytoin before bedtime and urine collection during two consecutive nights allow for an accurate determination of both phenotypes in the population. Expand
The N-demethylation of imipramine correlates with the oxidation of S-mephenytoin (S/R-ratio). A population study.
TLDR
Findings confirm those of an earlier panel study showing that the demethylation of imipramine and 2-OH-imipramines cosegregates in part with the mephenytoin oxidation polymorphism. Expand
Evidence that CYP2C19 is the major (S)-mephenytoin 4'-hydroxylase in humans.
TLDR
Data indicate that 2C19 is the principal determinant of (S)-mephenytoin 4'-hydroxylase activity in human liver. Expand
Mephenytoin hydroxylation deficiency in Caucasians: Frequency of a new oxidative drug metabolism polymorphism
TLDR
The ability of normal subjects to hydroxylate mephenytoin or debrisoquine after oral dosing was investigated in 156 unrelated Caucasians living in middle Tennessee, and it is suggested that 4‐hydroxylation of mephenYtoin is a new polymorphism independent of that for debrisquine. Expand
Biotransformation of moclobemide in humans
TLDR
The structure of the urinary metabolites formed after moclobemide administration in humans was elucidated, and the pattern compared with that in the plasma was found to be qualitatively but not quantitatively similar to that observed in urine. Expand
Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes
In 26 hospitalized patients with depression, a combined pharmacogenetic test with dextromethorphan, a substrate of cytochrome P450IID6, and mephenytoin, the S‐form of which is hydroxylated by aExpand
...
1
2
3
4
...